GSK said on Monday that it will receive up to $690 million from Italian drugmaker Alfasigma in exchange for the worldwide rights to Linerixibat, an investigational treatment aimed at relieving severe itching in patients with a rare liver condition.
The drug is designed to treat Cholestatic pruritus, a persistent internal itching sensation experienced by people with Primary biliary cholangitis (PBC), an autoimmune disorder in which the body’s immune system gradually damages the bile ducts in the liver.
Read Also – Agilent Technologies Moves to Acquire Biocare Medical in $950 Million Cash Deal
Alfasigma will pay GSK $300 million upfront, along with an additional $100 million if the drug receives approval in the United States by March 24. The company will also make a $20 million payment once regulators in Europe and the United Kingdom approve the treatment.
In addition, GSK could receive up to $270 million in sales-based milestone payments and will earn tiered double-digit royalties from global sales. Alfasigma already markets liver disease treatments in more than 100 countries worldwide.
About Alfasigma
Alfasigma is a global pharmaceutical company founded more than 75 years ago in Italy, with headquarters in Bologna and Milan. The company employs around 4,000 people who work across research, development, manufacturing, and distribution of medicines. Alfasigma aims to improve health and quality of life for patients, caregivers, and healthcare professionals by providing effective and safe medical solutions. The company mainly focuses on three therapeutic areas: gastroenterology, vascular diseases, and rheumatology. Its product portfolio includes treatments used in both primary and specialized care, as well as medications for rare diseases and consumer health products. In addition to prescription medicines, Alfasigma also offers over-the-counter products, medical foods and nutraceuticals, supporting a broad range of healthcare needs.
